A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Active, not recruiting · Phase 3 · NCT04819100
Conditions: Carcinoma, Non-Small-Cell Lung
At a glance
- Research payments reported, 2025
- $803,188
- U.S. investigators named
- 8
- Sites paid
- 9
- Planned or actual enrollment
- 152
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- Selpercatinib (drug), Placebo (drug)
- Dates
- Started 2021-12-20; completion 2028-05
- Results posted
- Not yet
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
From ClinicalTrials.gov, last updated 2026-03-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $803,188 in research payments for this study in 2025 (28 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jonathan W. Goldman, M.D. Hematology & Oncology · Santa Monica, CA
- Venkat Pavan R. Kancharla, M.D Medical Oncology · Palm Bay, FL
- Narjust Florez, M.D. Medical Oncology · Boston, MA
- Fawzi Abu Rous, MD Medical Oncology · Lansing, MI
- K. R. Shen, MD Cardiothoracic Surgery · Rochester, MN
- Alexander Edward D. Drilon, MD Medical Oncology · New York, NY
- Vivian Cline, MD Medical Oncology · Round Rock, TX
- Krista Isaac, D.O. Hematology & Oncology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $215,427
- Memorial Sloan-Kettering $212,731
- US Oncology Research LLC $139,865
- Ronald Reagan UCLA Medical Center, CA $82,495
- Alliance Cancer Specialists PC $46,735
- Cancer Care Centers of Brevard, Inc. $31,772
- Dana Farber PArtners Cancer Care Inc $31,678
- Mayo Clinic $30,145
- Texas Oncology PA $7,341
- Henry Ford Health Hospital, MI $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.